AstraZeneca is heading towards approval of their leading Antibody-Drug Conjugate (Enhertu) for all solid tumors that are HER2+. This would be the first ADC with a "tumor agnostic" indication.
This would represent a breakthrough for AZ certainly, but more importantly for patients who have unresectable / metastatic tumors with little to no option for treatment. Biliary tract, bladder, cervical, endometrial, ovarian, and pancreatic cancers are all potentially treatable with significant improvements to survival benefits.
AZ's partner with this ADC - Daiichi - has more promising products in the pipeline, with Merck earlier this year plunking down several billion to get involved.
https://lnkd.in/ggu9qSS8
Congratulations!